From Nasdaq:



The guru fundamental report for CRISPR THERAPEUTICS AG (CRSP) rates the stock highest based on Benjamin Graham’s value investor model. This methodology looks for stocks with low P/B and P/E ratios, low debt, and solid long-term earnings growth. CRSP is a mid-cap value stock in the Biotechnology & Drugs industry, with a rating of 43% based on the firm’s underlying fundamentals and stock valuation. The stock did not meet all criteria in the strategy’s test, but it showed strengths in sales, current ratio, and long-term debt in relation to net current assets. Benjamin Graham, known as the “Father of Value Investing”, mentored investors like Warren Buffet and inspired others such as John Templeton and Mario Gabelli.

Validea, an investment research service, offers stock analysis and model portfolios based on investment legends’ published strategies, including Warren Buffet, Benjamin Graham, Peter Lynch, and Martin Zweig. For more information about Validea, visit their website.



Read more: Benjamin Graham Detailed Fundamental Analysis – CRSP